AMENDMENTS TO THE CLAIMS

1. (currently amended) A compound of formula **(I)**,



(I)

or a pharmaceutically acceptable ~~derivative~~ salt thereof, wherein:

X ~~represents~~ is NR ~~or O~~;

R ~~represents~~ is hydrogen, C_{1-8} alkyl or $SO_2[C_{1-8}$ alkyl];

W ~~represents~~ is N ~~or CH~~;

Y and Y' are each independently ~~represent~~ hydrogen, halogen, OH, CF_3, OCF_3, CN, NH_2, C_{1-8} alkyl, C_{1-8} alkyloxy or C_{3-8} cycloalkyl;

Ring A ~~represents a heterocyclic~~ is a piperidine ring ~~containing at least one nitrogen atom;~~

Z ~~represents~~ is a direct ~~link~~ bond, C_{1-8} alkyl or C_{3-8} cycloalkyl;

R^1 ~~represents~~ is R^2, OR^2, OR^3-R^4, $N(R^2)[C_{1-8}$ alkylene$]_aR^4$; $NCOR^2$, or SR^4;

R^2 and R^4 are each independently ~~represent~~ hydrogen, C_{3-8} cycloalkyl, CF_3, Ar or Het;

R^3 ~~represents~~ is a direct ~~link~~ bond or C_{1-8} alkyl;

a is 0 or 1;

Ar ~~represents~~ is an aromatic ring, optionally fused to a heterocyclic ring, ~~and/or~~ wherein said Ar is optionally substituted with one ~~or more groups as described below~~ to three groups independently selected from halogen, C_{1-8}alkyl, C_{1-8}alkyloxy, $S[C_{1-8}$alkyl], CN, CF_3, NH_2 and OH;

Het ~~represents~~ is a heterocyclic ring optionally ~~substituted with one or more groups as described below, and/or optionally~~ fused to an aromatic ring, wherein said Het ~~which~~ is optionally substituted with one ~~or more~~ to three groups ~~as described below~~ independently selected from halogen, C_{1-8}alkyl, C_{1-8}alkyloxy, $S[C_{1-8}$alkyl], CN, CF_3, NH_2 and OH; and

at each occurrence C_{1-8}alkyl, C_{1-8}alkylene and C_{3-8}cycloalkyl may be independently optionally substituted with one ~~or more~~ to three groups ~~as described below;~~

~~substituent groups for Ar, Het, C_{1-8}alkyl, C_{1-8}alkylene and C_{3-8}cycloalkyl referred to above are~~ independently selected from ~~hydrogen,~~ halogen, C_{1-8}alkyl, C_{1-8}alkyloxy, $S[C_{1-8}$alkyl], CN, CF_3, NH_2 and OH.

2. (currently amended) ~~A~~ The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein ~~X represents NR and R represents Me~~ R is methyl.

3. (currently amended) ~~A~~ The compound according to claim 1 or claim 2, or a pharmaceutically acceptable salt thereof wherein Y is chloro and Y' is hydrogen ~~W represents N~~.

4. (currently amended) ~~A~~ The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof wherein R^1 is a group selected from phenyl, indolyl, pyridyl, pyrazolyl, benzofuranyl, benzoimidazolyl, benzooxadiazolyl, phenoxy, piperidinyl, tetrahydofuranyl, cyclopropyl, cyclopentyl, cyclohexyl, isopropyl or butyl, wherein said R^1 group is optionally substituted with one to three groups independently selected from halogen, $C_{1\text{-}8}$alkyl, $C_{1\text{-}8}$alkyloxy, S[$C_{1\text{-}8}$alkyl], CN, CF_3, NH_2 and OH ~~Ring A represents piperidinyl~~.

5. (currently amended) ~~A~~ The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof wherein Z is a direct ~~link~~ bond.

6. (currently amended) A compound ~~according to claim 1,~~ selected from

[4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulen-1-yl)-piperidin-1-yl]-(1H-indol-3-yl)-methanone;

1-[4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e] azulen-1-yl)-piperidin-1-yl]-2-o-tolyl-ethanone;

[4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulen-1-yl)-piperidin-1-yl]-(1-methyl-cyclohexyl)-methanone;

1-[4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e] azulen-1-yl)-piperidin-1-yl]-2-cyclopropyl-ethanone;

[4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulen-1-yl)-piperidin-1-yl]-(1H-indol-2-yl)-methanone;

[4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulen-1-yl)-piperidin-1-yl]-(2-hydroxy-5-methyl-phenyl)-methanone;

[4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulen-1-yl)-piperidin-1-yl]-(1H-indol-6-yl)-methanone;

[4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulen-1-yl)-piperidin-1-yl]-(3-methoxy-phenyl)-methanone;

[4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulen-1-yl)-piperidin-1-yl]-(3-fluoro-phenyl)-methanone;

[4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulen-1-yl)-piperidin-1-yl]-(4-fluoro-phenyl)-methanone;

1-[4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulen-1-yl)-piperidin-1-yl]-butan-1-one; and

[4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulen-1-yl)-piperidin-1-yl]-cyclopropyl-methanone; ~~and~~ or a

pharmaceutically acceptable ~~derivatives~~ salt thereof.

7. The ~~use of a~~ compound ~~according to any of claims 1 to 6 as a medicament~~ [4-(8-Chloro-5-methyl-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulen-1-yl)-piperidin-1-yl]-(1H-indol-3-yl)-methanone or a pharmaceutically acceptable salt thereof.

8. A method of treating ~~treatment of anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary),~~ primary dysmenorrhea, secondary dysmenorrhea, endometriosis, ~~emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittelschmerz, preclampsia,~~ premature ejaculation, ~~premature (preterm)~~ or preterm labor ~~or Raynaud's disease~~, comprising administering a therapeutically effective amount of a compound according to any one of claims 1 to 6 to a patient ~~suffering from such a disorder~~ in need of treatment thereof.

9. (currently amended) ~~A~~ The method according to claim ~~7~~ 8 wherein ~~the disorder is dysmenorrhoea (primary or secondary)~~ primary dysmenorrhea or secondary dysmenorrhea is treated.

10. (currently amended) ~~A~~ The method according to claim 9 wherein ~~the disorder is~~ primary ~~dysmenorrhoea~~ dysmenorrhea is treated.

11. (currently amended) The ~~use of a compound according to any of claims 1 to 6 in the manufacture of a medicament for the treatment of anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittelschmerz, preclampsia,~~ method according to claim 8 wherein premature ejaculation~~, premature (preterm) labor or Raynaud's disease~~ is treated.

12. (currently amended) ~~Use~~ The method according to claim ~~11~~ 8 wherein ~~the disorder is dysmenorrhoea (primary or secondary)~~ preterm labor is treated.

13. (canceled)

14. (currently amended) A pharmaceutical ~~formulation including~~ composition comprising a compound according to any one of claims 1 to 6 or a pharmaceutically acceptable ~~derivative~~ salt thereof, together with a pharmaceutically acceptable ~~excipients,~~ excipient, diluent or ~~carrier;~~ carrier.

15. (canceled)